SCHEMBL20074641

SCHEMBL20074641

CCn1cncc1-c1cc(C(=O)NC(C)(C)C)cc(-c2ccc(Cl)cc2)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.42
HTR7 P34969 3/20 0.41
HTR6 P50406 3/20 0.41
HTR1A P08908 2/20 0.41
KCNH2 Q12809 1/20 0.39
GSK3B P49841 1/20 0.38
DYRK1A Q13627 1/20 0.38
LMNA P02545 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
SCN10A Q9Y5Y9 4/20 0.37
HSD11B1 P28845 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
SCN2A Q99250 3/20 0.36
P2RY14 Q15391 1/20 0.36
ANO1 Q5XXA6 1/20 0.36
MAP4K4 O95819 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20074610 0.90 HTR6 (0.42) HTR7HTR6HTR1AGSK3BDYRK1A
SCHEMBL20074601 0.88 P2RY14 (0.48) HTR7HTR6HTR1AKCNH2CYP3A4
SCHEMBL20074817 0.86 GSK3B (0.52) CNR1GSK3BDYRK1AHSD11B1
SCHEMBL20074608 0.85 CNR1 (0.43) CNR1GSK3BDYRK1ALMNASCN10A
SCHEMBL20074710 0.83 GSK3B (0.43) CNR1KCNH2GSK3BDYRK1ACYP3A4
SCHEMBL19641901 0.80 HTT (0.42) CNR1LMNAHSD11B1
SCHEMBL18496602 0.78 SCN10A (0.46) CNR1LMNASCN10AHSD11B1SCN2A
SCHEMBL20075391 0.77 GSK3B (0.51) GSK3BDYRK1ALMNASCN10A
SCHEMBL20075362 0.76 WNT1 (0.39) GSK3BDYRK1ALMNASCN10AP2RY14
SCHEMBL18706164 0.76 CNR1 (0.43) CNR1LMNASCN10AHSD11B1SCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563049-B Imidazole compounds as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2022-11-29 CN claimed
EP-3526201-B1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-11-18 EP claimed
CN-109563049-B Imidazole compounds as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2022-11-29 CN disclosed
EP-3526201-B1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-11-18 EP disclosed
EP-3526201-B1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2020-11-18 EP disclosed
US-10556870-B2 Imidazole compounds as EAAT3 inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-02-11 US disclosed
US-10556870-B2 Imidazole compounds as EAAT3 inhibitors HOFFMANN-LA ROCHE INC. (US) 2020-02-11 US disclosed
US-20190233379-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-08-01 US disclosed
US-20190233379-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2019-08-01 US disclosed
WO-2018069362-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10556870-B2 Imidazole compounds as EAAT3 inhibitors SLC1A1, SLC1A3, SLC1A2 CNR1 2639/4885HTR7 1612/4885HTR6 1173/4885
US-20190233379-A1 IMIDAZOLE COMPOUNDS AS EAAT3 INHIBITORS SLC1A1, SLC1A3, SLC1A2 CNR1 2639/4885HTR7 1612/4885HTR6 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.